Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (888)	4/13/1998 11:43:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

Chucka, How does your response address Bob's question or IZP's technology? Researchers find protein that protects cancer WASHINGTON (AP) - Researchers have found a protein that gives cancer cells a resistance against radiation and chemotherapy by blocking a natural process that usually causes cells to die. In studies to be published today in the journal Science, three teams of researchers report that laboratory tests show that cancer cells have a protective protein, called nuclear factor kappa B, or NF-KB, that blocks a natural cell-killing action. The research was conducted at Massachusetts Institute of Technology in Cambridge, Mass., the Salk Institute in La Jolla, Calif., and the University of North Carolina in Chapel Hill, N.C. Earlier research had found that when cancer is treated with chemotherapy or radiation, the cells are forced to go through a process called apoptosis, a type of cell suicide.Apoptosishrnm- The studies showed that NF-KB prevented the cancer cells from going through apoptosis, thus giving cancer a resistance to radiation and chemotherapy. In the MIT laboratories, researchers blocked the action of NF-KB in both tumor and non-tumor cells. The cells were then treated with tumor necrosis factor, or TNF. Cells of both types were killed. TNF is a natural cancer cell killer. Earlier studies had shown that cells with active NF-KB could not be killed by TNF. At Salk, researchers also inhibited NF-KB and found that cancer cells could be more easily killed. The researchers said the work suggests that drugs that block the action of NF-KB could be used to treat both cancer and some bacterial and viral infections. Researchers at the University of North Carolina blocked the action of NF-KB in cultured tumor cells and found that the cells could be more easily killed by both chemotherapy agents and by radiation.ÿ

To: Chuca Marsh who wrote (888)	5/7/1998 8:32:00 PM
From: Coho	Read Replies (1) \| Respond to of 1501

Chuca I'm back. What does this tell you? <<He has expertise in building infrastructure, negotiating business development agreements and leading research and clinical programs from early phase I to regulatory approval. The Board believes that Mr. McBeath's international experience and contacts will be invaluable as Inflazyme enters its next stage of development in seeking strategic alliances with multinational pharmaceutical partners. >> Here we go again, but this time its for real! It was only a matter of time until the major stock holders (underwriters) put their man in charge with, IMHO, a mandate to do a deal, finally!!! As you know I bailed out a year ago or so with my profits. I have been lurking ever since waiting for this opportunity. My expectations is a major deal,(JV, Licence, sellout etc.) before September. Dr. Salari tempted us for years with the possibility of a major deal. This time there will be no talk, just results! To our benevolent and ethical investors on the thread, this is also excellent news as the testing and approval process will be fast tracked. Anyone else on the thread excited about our new CEO?